×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Nanomedicines and Nanosimilars – Implications for Regulators, Payers and Prescribers
Session Chair(s)
Hubert Leufkens, PharmD, PhD
Emeritus Professor of Pharmaceutical Policy and Regulatory Science
Utrecht University, Netherlands
Nanomedicines and Nanosimilars – Implications for Regulators, Payers and Prescribers
Speaker(s)
Regulatory Considerations for the Approval of Nanomedicines and Nanosimilars Regulatrory Considerations for the Approval of Nanomedicines and Nanosimilars
Beatriz Silva Lima, PharmD, PhD
University of Lisbon, Portugal
Director of FFUL, Faculty of Pharmacy
Clinical Perspective of the Potential Implications of Nanosimilars What are Nanomedicines and How Do They Differ from ‘Traditional’ Small Molecules?
Gerrit Borchard
University of Geneva, Switzerland
Have an account?